Rituximab Products (Rituxan®, Truxima®, Riabni™, Ruxience®) — Non‑Oncology Indications
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and prior authorization requirements for rituximab products (Rituxan, Truxima, Riabni, Ruxience) when used for non-oncology indications such as rheumatoid arthritis, vasculitides, autoimmune neurologic and dermatologic diseases, and transplant-related uses for Blue Cross Blue Shield Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Rituximab Products (Non‑Oncology)
Rheumatoid Arthritis — Initial Therapy
Authorization of 12 months may be granted for treatment of adults with moderately to severely active RA when ALL of the following criteria are met:
RA initial criteria
- Biomarker testing options: Either: positive anti-cyclic citrullinated peptide (anti-CCP) OR positive rheumatoid factor (RF); OR the member has been tested for ALL of anti-CCP, RF, and C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR).
Laboratory results required for initial requests.
- Methotrexate/leflunomide and prior therapy requirement: Either: the requested medication is prescribed in combination with methotrexate or leflunomide; OR the member has a documented clinical reason not to use methotrexate or leflunomide. If prescribed in combination with methotrexate, the member must have experienced an inadequate response to at least a 3-month trial of methotrexate titrated to ≥15 mg/week. If methotrexate was not tolerated or is contraindicated, the member must have had an inadequate response to another conventional agent (e.g., hydroxychloroquine, leflunomide, sulfasalazine).MTX ≥15 mg/week for ≥3 months when trialed
See Appendix for permitted MTX contraindications/intolerances; documentation of prior medication trials required.
Other Indications — Authorization Durations
Authorization may be granted when criteria for the indicated condition are met:
Requires documentation of prior medication trials.
Requires prior failure of corticosteroids/other immunosuppressives.
Cryoglobulinemia
Covered when ALL of the following are met for cryoglobulinemia
Documentation of prior corticosteroid and immunosuppressive therapy failure required.
Solid organ transplant
Covered when ALL of the following are met for solid organ transplant
Opsoclonus-myoclonus-ataxia
Covered when ALL of the following are met for opsoclonus-myoclonus-ataxia
Documentation of refractoriness to steroids and chemotherapy required.
Systemic lupus erythematosus
Covered when ALL of the following are met for systemic lupus erythematosus (SLE)
Documentation of refractoriness to immunosuppressive therapy required.
Myasthenia gravis
Covered when ALL of the following are met for myasthenia gravis
Refractory disease required; documentation of prior therapies and inadequate response expected.
Membranous nephropathy
Covered when ALL of the following are met for membranous nephropathy
Risk stratification (moderate/high) must be documented.
Susac syndrome
Covered when ALL of the following are met for Susac syndrome
Rheumatoid arthritis — continued treatment
Covered when ALL of the following are met for rheumatoid arthritis (continuation treatment)
At least two doses must have been administered; chart notes documenting improvement required.
Relapsing‑remitting multiple sclerosis — reauthorization
Covered when ALL of the following are met for relapsing‑remitting multiple sclerosis (reauthorization)
Documentation of stability or improvement required.
Other indications — continued treatment
Covered when ALL of the following are met for other indications (continuation)
Ongoing clinical benefit must be demonstrated; documentation required.
Covered Indications with Dosing
Coverage for rituximab biosimilars includes specified indications with corresponding IV dosing regimens:
Prior authorization must reflect indication-specific dosing and intervals; see dosing detail for age restrictions and minimum intervals (not sooner than 16 weeks for some indications).
Requests for concomitant use of rituximab products (Rituxan, Ruxience, Truxima, Riabni) with other biologic or targeted synthetic disease‑modifying agents are not permitted and will be excluded. Specifically, members will not receive rituximab products concomitantly with other biologic or targeted synthetic drugs for rheumatoid arthritis, with other disease‑modifying multiple sclerosis agents (with the stated exception that Ampyra and Nuedexta are not disease‑modifying), or concomitantly with other biologics for neuromyelitis optica.
All indications not listed in this policy as FDA‑approved or supported by recognized compendia are considered experimental/investigational and not medically necessary. Coverage will be limited to FDA‑approved or compendial uses described in the policy.
If methotrexate or leflunomide cannot be used, the prescriber should document a clinical reason. Acceptable clinical reasons include conditions such as alcohol use disorder, chronic liver disease, significant drug interactions, pregnancy or planning pregnancy, breastfeeding, hypersensitivity, history of intolerance or other significant comorbidity that would make methotrexate or leflunomide unsafe or inappropriate; documentation of the specific reason is required to support use of alternative therapies.
Per Tennessee statute, off‑label uses of FDA‑approved drugs are eligible for coverage only when the off‑label indication is recognized in one of the statutorily recognized standard reference compendia or in the published peer‑reviewed medical literature. Absence of such compendia or literature support may result in exclusion of the off‑label request.
Consistent with the policy exclusions, any request for an indication that is not specified in this policy as FDA‑approved or compendial will be considered experimental/investigational and not medically necessary unless the request meets the Tennessee compendia/literature requirements described above.
For indications not explicitly listed in this policy (non‑specified or off‑label uses), authorization may only be considered if the indication is supported by a statutorily recognized compendium or published peer‑reviewed medical literature. If no such compendia or literature support exists for the requested indication, the request will be treated as not medically necessary and may be denied.
Coding, Dosing and Administration
| Rituxan / Rituximab | IV 1000 mg every 2 weeks or 375 mg/m2 weekly; various induction/maintenance regimens by indication |
| Truxima (Rituximab-abbs) | IV 1000 mg every 2 weeks or 375 mg/m2 weekly; indication-specific regimens |
| Riabni (Rituximab-arrx) | IV 1000 mg every 2 weeks or 375 mg/m2 weekly; indication-specific regimens |
| Ruxience (Rituximab-pvvr) | IV 1000 mg every 2 weeks or 375 mg/m2 weekly; indication-specific regimens |
| not provided | No specific CPT/HCPCS/NDC billing codes listed in these chunks; dosing and administration routes provided instead. |
Provider Actions, Prior Authorization and Documentation
Prior Authorization Required
Prior Authorization Required — PA required; durations vary by indication (commonly 12 months; 3 months for solid organ transplant). Authorizations must reflect the indication-specific duration listed in the policy (for example: RA — 12 months; solid organ transplant — 3 months).
- Durations commonly 12 months for most indications; 3 months for solid organ transplant.
Step Therapy May Apply
Step therapy may apply for some non-oncology indications. Providers should consult the Step Therapy Requirements for Provider Administered Specialty Medications for specific step requirements prior to submitting a prior authorization request.
- See: Step Therapy Requirements for Provider Administered Specialty Medications: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf
Indication-specific Prior Authorization Durations
Indication-specific prior authorization durations: authorizations are generally for 12 months for most indications (e.g., RA, GPA/MPA, EGPA, pauci-immune glomerulonephritis, Sjögren's syndrome, MS, NMOSD, autoimmune blistering disease, opsoclonus-myoclonus-ataxia, systemic lupus erythematosus, myasthenia gravis, membranous nephropathy, Susac syndrome, cryoglobulinemia). Solid organ transplant and prevention of antibody-mediated rejection: 3 months. Reauthorization criteria and durations are described per indication.
- Most indications: 12-month authorizations.
- Solid organ transplant: 3-month authorization.
Prior authorization must match indication-specific dosing
Prior authorization must match indication-specific dosing and administration schedules. Requests should reflect regimen, dose, frequency and route consistent with the indication (e.g., RA: 1000 mg x 2 doses 2 weeks apart with subsequent courses every ~24 weeks or based on clinical evaluation; alternative dosing schedules per product labeling for MS, SLE, cryoglobulinemia, membranous nephropathy, etc.). Consult the policy dosing tables or standard compendia for exact regimens.
- Documented dose and frequency must align with indication-specific regimens in the policy or standard compendia.
- Do not request dosing or intervals that are more frequent than indicated (examples in product-specific dosing tables).
Rheumatoid arthritis reauthorization requirement
Rheumatoid arthritis reauthorization requires documentation of clinical benefit. Continued treatment (including new members) is approved only when there is evidence of a positive clinical response after at least two doses — defined as ≥20% improvement from baseline in tender joint count, swollen joint count, pain, or disability.
- Reauthorization requires ≥20% improvement from baseline in one or more RA activity measures (tender/swollen joint counts, pain, disability).
- Must document response after at least two doses of therapy.
Tennessee off-label coverage requirement
BlueCross BlueShield of Tennessee follows state requirements for off-label coverage. Off-label uses will be considered only when recognized in a statutorily recognized standard reference compendium or in the published peer‑reviewed medical literature per Tennessee mandate.
- Off-label coverage limited to uses supported by state-recognized compendia or peer-reviewed literature (Tennessee Code Annotated Section 56-7-2352).
Required Documentation
Required documentation for PA review — Initial requests: provide laboratory results, chart notes, or medical record documentation of biomarker testing when applicable (e.g., RF, anti-CCP, CRP and/or ESR); chart notes or medication history supporting prior medications tried and response to therapy, or clinical reason to avoid a therapy. Continuation requests: provide chart notes or medical record documentation supporting positive clinical response. For certain indications (e.g., Sjögren's syndrome, cryoglobulinemia, opsoclonus-myoclonus-ataxia, SLE) initial requests must include documentation of prior medications tried and responses.
- Initial: biomarker labs (RF, anti-CCP, CRP/ESR) when applicable.
- Initial: prior medication history and response, or reason to avoid therapies.
- Continuation: documentation of positive clinical response.
- Certain indications require documentation of prior corticosteroid or immunosuppressive failure.
Reference documentation requirement
Reference documentation requirement — consult standard compendia (e.g., NCCN Guidelines®, Drugdex/Micromedex, AHFS Drug Information) or the policy dosing tables for appropriate regimens, dosing, contraindications, precautions, warnings, and monitoring information when preparing PA requests.
- Refer to NCCN, Drugdex (Micromedex), or AHFS for regimen and dosing guidance as needed.
Step Therapy Guidance and Prior therapy / refractoriness requirements
Step Therapy Guidance — when step therapy is applicable, follow the Step Therapy Requirements guide for Provider Administered Specialty Medications. Some authorizations require prior failure or refractoriness to corticosteroids or other immunosuppressive agents; include documentation of prior therapy trials and refractoriness when required by the indication.
- See the BCBST Step Therapy guide for specific agent-level requirements.
- Document prior failures or refractoriness to corticosteroids/immunosuppressives where noted (e.g., Sjögren's syndrome, cryoglobulinemia, opsoclonus-myoclonus-ataxia, SLE).
Definitions and Reference Concepts
Background
Rituximab is an anti‑CD20 monoclonal antibody that produces clinical benefit by depleting CD20‑expressing B lymphocytes. It is used across a range of autoimmune, inflammatory and transplant‑related conditions; this policy lists covered FDA‑approved indications and selected compendial uses where prior authorization criteria and dosing regimens are specified.
Revision History
Medical Policy Manual approved; do not implement until effective date of 06/30/2026 (EFFECTIVE DATE 6/30/2026).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.